指南与共识临床免疫分子诊断质量管理与危急值

IFCC 关于 SARS-CoV-2 抗原快速即时检测的暂行指南

IFCC interim guidelines on rapid point-of-care antigen testing for SARS-CoV-2 detection in asymptomatic and symptomatic individuals.
指南 / 共识 · Clin Chem Lab Med · 2021-04-28

该文件由国际临床化学与检验医学联合会(IFCC)COVID-19 工作组制定,旨在总结现有 SARS-CoV-2 抗原快速检测(Ag-RDTs)性能数据,并就临床指征、目标人群、检测选择与评估、结果解读与局限性及分析前考虑提供暂行指导,主要帮助实验室和受监管卫生专业人员选择、验证和实施获批的 Ag-RDTs。

要点

  • 核酸扩增检测(NAAT)仍是检测 SARS-CoV-2 的金标准。
  • 抗原检测可在特定情况下作为合适替代方案。
  • Ag-RDTs 用于检测生物标本中的病毒抗原蛋白以提示当前感染。

核心结论

  • 抗原检测可在特定情况下作为 NAAT 的合适替代方案。
  • 本文件提供 Ag-RDTs 的暂行指导以辅助实验室和卫生专业人员。

研究设计与样本

  • IFCC COVID-19 工作组制定的暂行指南,总结现有 Ag-RDTs 性能数据。

主要发现

  • Ag-RDTs 可检测鼻、鼻咽、唾液等标本中的病毒抗原蛋白以提示当前 SARS-CoV-2 感染。
  • 快速色谱免疫分析用于即时检测,相较传统仪器化实验室免疫分析各有优劣。

关键数值与推荐

  • NAAT 仍是检测和理论上量化 SARS-CoV-2 mRNA 的金标准。
  • 指导涵盖临床指征与目标人群、检测选择与评估、结果解读与局限性及分析前考虑。

临床怎么用

  • 帮助实验室和受监管卫生专业人员选择、验证和实施获批的 Ag-RDTs。
  • 用于临床管理及及时隔离感染者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

With an almost unremittent progression of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections all around the world, there is a compelling need to introduce rapid, reliable, and high-throughput testing to allow appropriate clinical management and/or timely isolation of infected individuals. Although nucleic acid amplification testing (NAAT) remains the gold standard for detecting and theoretically quantifying SARS-CoV-2 mRNA in various specimen types, antigen assays may be considered a suitable alternative, under specific circumstances. Rapid antigen tests are meant to detect viral antigen proteins in biological specimens (e.g. nasal, nasopharyngeal, saliva), to indicate current SARS-CoV-2 infection. The available assay methodology includes rapid chromatographic immunoassays, used at the point-of-care, which carries some advantages and drawbacks compared to more conventional, instrumentation-based, laboratory immunoassays. Therefore, this document by the International Federation for Clinical Chemistry and Laboratory Medicine (IFCC) Taskforce on COVID-19 aims to summarize available data on the performance of currently available SARS-CoV-2 antigen rapid detection tests (Ag-RDTs), providing interim guidance on clinical indications and target populations, assay selection, and evaluation, test interpretation and limitations, as well as on pre-analytical considerations. This document is hence mainly aimed to assist laboratory and regulated health professionals in selecting, validating, and implementing regulatory approved Ag-RDTs.

来源:Clin Chem Lab Med,查看原文。版权归原作者所有。

引用

  1. Bohn MK, Lippi G, Horvath AR, et al. IFCC interim guidelines on rapid point-of-care antigen testing for SARS-CoV-2 detection in asymptomatic and symptomatic individuals. Clin Chem Lab Med. 2021. PMID: 33908222. doi:10.1515/cclm-2021-0455

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。